Phase I and pharmacokinetic study of HGS-ETR2, a human monoclonal antibody to TRAIL R2, in patients with advanced solid malignancies
Simon Pacey(Royal Marsden NHS Foundation Trust), Johann S. de Bono(Royal Marsden NHS Foundation Trust), Sarah P. Blagden(Churchill Hospital), A. Corey(Human Genome Sciences (United States)), A H Calvert(Utrecht University), C. Bale(Human Genome Sciences (United States)), Gerhardt Attard(London Cancer), N. L. Fox(Human Genome Sciences (United States)), Ruth Plummer(National Health Service)
Cited by 22
Related Papers
Integrative Clinical Genomics of Advanced Prostate Cancer
|Cell|2015|3.6k
Enzalutamide in Metastatic Prostate Cancer before Chemotherapy
|New England Journal of Medicine|2014|3k
Abiraterone in Metastatic Prostate Cancer without Previous Chemotherapy
|New England Journal of Medicine|2012|2.8k
DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer
|New England Journal of Medicine|2015|2.2k
Trial Design and Objectives for Castration-Resistant Prostate Cancer: Updated Recommendations From the Prostate Cancer Clinical Trials Working Group 3
|Journal of Clinical Oncology|2016|1.6k